Faculty introduction, disclosures

Introductory content and review of mPC [Learning Objective #1] Statistics, prognosis · Healthcare burden

Treatment considerations for mPC, including guideline-based approaches and clinical trial evidence Goals of therapy Castration-sensitive disease Docetaxel A second-generation antiandrogen An androgen synthesis inhibitor Low-risk/-volume vs. high-risk/-volume disease ADT plus Monitoring Genetic sequencing Considerations in specific circumstances BRCA or HRR mutations MSI/dMMR, TMB, or CDK12 mutations Clinically asymptomatic patients without visceral metastases Bony metastases PSMA-positive disease Disease flare prevention · Castration-resistant disease: treatment history and other considerations · Updates in investigational therapies Treatment challenges and gaps in care, including adverse effect identification and management  Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Summarize challenges related to the healthcare burden and treatment of metastatic prostate cancer (mPC).
• Describe the role of current and emerging pharmacotherapies in different treatment lines and factors impacting therapeutic decision-making in mPC.
• Develop a treatment plan for a patient with mPC.

ACCME Activity #202840993

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: David Wise, MD, PhD, Assistant Professor of Urology, NYU ‐ New York University School of Medicine, received financial compensation from Leap Therapeutics, Pfizer, Bayer, K36, Sanofi, Oncoc4, Accutar, Astra Zeneca for consulting.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL NOT discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck. 

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version